“You lose mostly muscle on GLP-1s, not fat.”
What the evidence shows
In the STEP 1 DXA substudy of semaglutide, total fat mass fell about 19% while lean body mass fell about 10%, and lean mass as a share of total body weight actually rose by roughly 3 percentage points — so the majority of weight lost was fat, not muscle. Real-world DXA studies (e.g., SEMALEAN) echo this: fat mass dropped, lean mass declined modestly then stabilized, and grip strength and sarcopenic-obesity rates improved.
What we still don’t know
We don't know the optimal protein intake and resistance-training "dose" to minimize lean loss specifically during GLP-1 treatment, especially in older adults, or the long-term functional consequences. DXA also can't cleanly separate contractile muscle from water, organ, and connective tissue, so "lean mass" change overstates true muscle change.
Why the claim misleads
The phrase "mostly muscle" inverts the data — the bulk of the weight lost is fat — but it has a real kernel: lean tissue does fall (loosely ~20–40% of total weight lost, similar to diet-only weight loss), which matters most for older or sedentary people. The honest takeaway is that lean loss is a manageable side issue addressed with adequate protein and resistance training, not a reason the treatment "doesn't work" or that you're melting muscle.
Graded by The Peptide Era · evidence, not hype